Caligan Partners LP
CIK 1727492 · View on SEC EDGAR ↗
- Portfolio value
- $2.1B
- Positions
- 28
- As of
- June 30, 2026
Portfolio value QoQ: +41.5% 13F does not disclose cash
- Top 10 holdings weight
- 80.89%
- Top 25 holdings weight
- 99.66%
- Positions above 1%
- 19
- Effective number of positions
- 7.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 15.43% Est. buys $296,762,533 · sells $279,852,022
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 53.8% still held
- New positions
- 5
- Increased
- 11
- Decreased
- 3
- Closed
- 4
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +140.0% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.3% · Options excluded: 5.3%
Sector breakdown
Full portfolio 28 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| LQDA Liquidia Corporation - Common Stock | $647,319,259 | 30.45% | 8,118,892 | $340,912,275 | |||
| RVMD Revolution Medicines, Inc. - Common Stock | $367,404,968 | 17.28% | 1,961,795 | $206,669,390 | Up ×5 | ||
| ABVX Abivax SA - American Depositary Shares | $207,608,952 | 9.77% | 1,557,924 | $44,823,715 | Up ×2 | ||
| PCVX Vaxcyte, Inc. - Common Stock | $127,225,411 | 5.99% | 2,188,636 | $7,477,030 | Up ×2 | ||
| EXEL Exelixis, Inc. - Common Stock | $84,512,985 | 3.98% | 1,553,262 | $17,893,578 | |||
| TNGX Tango Therapeutics, Inc. - Common Stock | $78,153,220 | 3.68% | 2,500,103 | $27,761,166 | Up ×1 | ||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $58,468,244 | 2.75% | 3,163,866 | $34,057,351 | Up ×3 | ||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $53,717,020 | 2.53% | 889,944 | $-27,287,500 | Down ×1 | ||
| ADMA ADMA Biologics Inc - Common Stock | $47,918,309 | 2.25% | 5,725,007 | $5,062,145 | Up ×3 | ||
| RVMD Revolution Medicines, Inc. - Common Stock | $47,157,104 | 2.22% | 251,800 | Call option | $24,896,579 | Up ×1 | |
| LBRX LB Pharmaceuticals Inc - Common Stock | $46,672,562 | 2.20% | 1,438,070 | $12,043,836 | |||
| IMCR Immunocore Holdings plc - American Depositary Shares | $43,856,815 | 2.06% | 1,381,317 | Up ×1 | |||
| VRDN Viridian Therapeutics, Inc. - Common Stock | $40,303,431 | 1.90% | 2,193,981 | Up ×1 | |||
| VOR Vor Biopharma Inc. - Common Stock | $35,440,465 | 1.67% | 1,925,066 | $1,097,288 | |||
| SABS SAB Biotherapeutics, Inc. - Common Stock | $31,072,107 | 1.46% | 7,967,207 | $557,704 | |||
| IVA Inventiva S.A. - American Depository Shares | $30,856,862 | 1.45% | 8,163,191 | $3,246,134 | Up ×2 | ||
| AURA Aura Biosciences, Inc. - Common Stock | $30,517,561 | 1.44% | 4,298,248 | $28,979,771 | Up ×1 | ||
| TYRA Tyra Biosciences, Inc. - Common Stock | $25,775,133 | 1.21% | 806,986 | $-23,132,741 | Down ×1 | ||
| IRD Opus Genetics, Inc. - Common Stock | $24,976,815 | 1.17% | 6,077,084 | $-2,664,562 | Up ×1 | ||
| ANIK Anika Therapeutics Inc. - Common Stock | $20,995,952 | 0.99% | 1,435,130 | $186,567 | |||
| SGMT Sagimet Biosciences Inc. - Series A Common Stock | $19,325,000 | 0.91% | 2,500,000 | Up ×1 | |||
| ARTV Artiva Biotherapeutics, Inc. - Common Stock | $16,840,277 | 0.79% | 1,736,111 | Up ×1 | |||
| SNSE Sensei Biotherapeutics, Inc. - Common Stock | $15,736,675 | 0.74% | 629,467 | $11,765,092 | Up ×1 | ||
| MBX MBX Biosciences, Inc. - Common Stock | $11,040,000 | 0.52% | 200,000 | $-14,290,412 | Down ×1 | ||
| VRCA Verrica Pharmaceuticals Inc. - Common Stock | $5,654,329 | 0.27% | 923,910 | $766,845 | |||
| AGIO Agios Pharmaceuticals, Inc. - Common Stock | $3,339,900 | 0.16% | 90,000 | Call option | $295,200 | ||
| ADMA ADMA Biologics Inc - Common Stock | $2,511,000 | 0.12% | 300,000 | Call option | $-192,000 | ||
| CLRB Cellectar Biosciences, Inc. - Common Stock | $1,306,594 | 0.06% | 469,998 | Up ×1 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| LQDA | Price move only | +0 | +$340.9M |
| RVMD | Bought more | +309K | +$206.7M |
| ABVX | Bought more | +96K | +$44.8M |
| AVTX | Bought more | +1.5M | +$34.1M |
| TNGX | Bought more | +91K | +$27.8M |
| XENE | Trimmed | -503K | -$27.3M |
| RVMD | Bought more | +23K | +$24.9M |
| TYRA | Trimmed | -470K | -$23.1M |
| EXEL | Price move only | +0 | +$17.9M |
| MBX | Trimmed | -649K | -$14.3M |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| VRNA | Sept. 30, 2025 | 1,436,878 | $135,899,921 | No longer tracked |
| MLYS | June 30, 2026 | 2,772,654 | $75,111,197 | -2.9% |
| CGON | June 30, 2026 | 900,000 | $60,912,000 | 11.1% |
| SYRE | June 30, 2026 | 878,127 | $44,292,726 | 19.3% |
| INBX | March 31, 2026 | 473,565 | $37,411,635 | 47.3% |
| EOLS | Dec. 31, 2025 | 4,138,943 | $25,413,110 | 26.0% |
| SAGE | June 30, 2025 | 3,052,538 | $24,267,677 | No longer tracked |
| RAPT | March 31, 2026 | 644,400 | $21,825,828 | No longer tracked |
| MRUS | Dec. 31, 2025 | 216,954 | $20,426,219 | No longer tracked |
| MAZE | June 30, 2026 | 614,962 | $18,356,616 | -0.6% |
| YMAB | Sept. 30, 2025 | 2,342,609 | $10,565,167 | No longer tracked |
| RZLT | Sept. 30, 2025 | 1,543,014 | $6,881,842 | -50.4% |
| BCRX | Sept. 30, 2025 | 638,908 | $5,724,616 | 29.6% |
| SLS | Dec. 31, 2025 | 2,300,000 | $3,703,000 | 264.7% |
| SPRB | March 31, 2026 | 20,514 | $1,786,975 | -21.3% |
| AURA | Dec. 31, 2025 | 227,174 | $1,403,935 | 37.8% |
| ENTA | March 31, 2025 | 184,826 | $1,062,750 | 144.4% |
| ELDN | March 31, 2026 | 555,978 | $839,527 | 14.6% |